Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 531-535 |
| Number of pages | 4 |
| Journal | Annals of the Rheumatic Diseases |
| Volume | 68 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2009 |
Cite this
}
Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. / de Vries, M.K.; van der Horst - Bruinsma, I.E.; Nurmohamed, M.T.; Aarden, L.; Stapel, S.N.; Peters, M.J.L.; van Denderen, A.C.; Dijkmans, B.A.C.; Wolbink, G.
In: Annals of the Rheumatic Diseases, Vol. 68, No. 4, 2009, p. 531-535.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis
AU - de Vries, M.K.
AU - van der Horst - Bruinsma, I.E.
AU - Nurmohamed, M.T.
AU - Aarden, L.
AU - Stapel, S.N.
AU - Peters, M.J.L.
AU - van Denderen, A.C.
AU - Dijkmans, B.A.C.
AU - Wolbink, G.
PY - 2009
Y1 - 2009
N2 - Background: Immunogenicity, specifically the onset of antibodies against tumour necrosis factor (TNF) blocking agents, seems to play an important role in non-response to treatment with these drugs. Objectives: To assess the relation of clinical response of ankylosing spondylitis (AS) to etanercept with etanercept levels, and the presence of antibodies to etanercept. Methods: Patients with AS were treated with etanercept 25 mg twice weekly, according to the international Assessment in Ankylosing Spondylitis (ASAS) working group consensus statement. Sera were collected at baseline and after 3 and 6 months of treatment. Clinical response was defined as a 50% improvement or as an absolute improvement of 2 points on a (0-10 scale) Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score. Functional etanercept levels were measured by a newly developed ELISA, measuring the binding of etanercept to TNF. Antibodies against etanercept were measured with a two-site assay and antigen binding test. Clinical data were used to correlate disease activity with serum etanercept levels. Results: In all, 53 consecutive patients were included. After 3 months of treatment 40 patients (76%) fulfilled the response criteria. Mean etanercept levels were 2.7 mg/litre and 3.0 mg/litre after 3 and 6 months respectively. Characteristics and etanercept levels of responders and non-responders were similar. No antibodies to etanercept were detected with any of the assays. Conclusion: Etanercept levels of responders and non-responders were similar and no antibodies to etanercept were detected with any of the assays. This study indicates that etanercept is much less immunogenic compared with the other TNF-blocking agents
AB - Background: Immunogenicity, specifically the onset of antibodies against tumour necrosis factor (TNF) blocking agents, seems to play an important role in non-response to treatment with these drugs. Objectives: To assess the relation of clinical response of ankylosing spondylitis (AS) to etanercept with etanercept levels, and the presence of antibodies to etanercept. Methods: Patients with AS were treated with etanercept 25 mg twice weekly, according to the international Assessment in Ankylosing Spondylitis (ASAS) working group consensus statement. Sera were collected at baseline and after 3 and 6 months of treatment. Clinical response was defined as a 50% improvement or as an absolute improvement of 2 points on a (0-10 scale) Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score. Functional etanercept levels were measured by a newly developed ELISA, measuring the binding of etanercept to TNF. Antibodies against etanercept were measured with a two-site assay and antigen binding test. Clinical data were used to correlate disease activity with serum etanercept levels. Results: In all, 53 consecutive patients were included. After 3 months of treatment 40 patients (76%) fulfilled the response criteria. Mean etanercept levels were 2.7 mg/litre and 3.0 mg/litre after 3 and 6 months respectively. Characteristics and etanercept levels of responders and non-responders were similar. No antibodies to etanercept were detected with any of the assays. Conclusion: Etanercept levels of responders and non-responders were similar and no antibodies to etanercept were detected with any of the assays. This study indicates that etanercept is much less immunogenic compared with the other TNF-blocking agents
U2 - 10.1136/ard.2008.089979
DO - 10.1136/ard.2008.089979
M3 - Article
VL - 68
SP - 531
EP - 535
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
SN - 0003-4967
IS - 4
ER -